Table 2.
Various studies examining the incidence/recurrence of non-alcoholic fatty liver disease (de novo or recurrent), non-alcoholic steatohepatitis and Cirrhosis in the post-liver transplant population n (%)
| Ref. | Year of publication | Indication of transplant | Number of patients | Findings of NAFLD post-transplant | Findings of NASH post-transplant | Findings of cirrhosis post-transplant | Mean follow-up duration |
| Tanaka et al[66] | 2013 | Living donor transplant for NAFLD | 7 | 0 (0) | 1 (14) | None | 5.3 yr |
| Dureja et al[59] | 2011 | NAFLD | 88 | 34 (39) | 25 (28.4) | 3 (3.4) (reported as fibrosis grade 3/4) | 82 mo |
| Dumortier et al[60] | 2010 | Several indication | 599 | 131 (31.1) | 5 (3.8) | 3 (2.25) | 40 mo |
| Bhagat et al[61] | 2009 | Cryptogenic/NASH Cirrhosis vs alcoholic cirrhosis | 71 | N/A | 31 (33) | None | 1517 d |
| Lim et al[62] | 2007 | Non-NAFLD indication (18 HBV, 7 HCV, 5 others) | 30 | 12 (40) | 4 (13) | None | 44 mo |
| Seo et al[63] | 2007 | 68 various causes, 84% HCV | 68 | 121 (18) | 61 (9) | None | 28 mo |
| Ong et al[64] | 2001 | Cryptogenic cirrhosis | 51 | 13 (25.4) | 8 (15.7) | None | 26 mo |
| Contos et al[57] | 2001 | Cryptogenic/NASH cirrhosis | 30 | 30 (100) | 3 (10) | None | 3.5 yr |
| Charlton et al[65] | 2001 | NASH cirrhosis | 16 | 9 (60) | 5 (33) | 2 (12.5) | 28.1 mo |
1
De novo. HCV: Hepatitis C virus; HBV: Hepatitis B virus; NAFLD: Non-alcoholic fatty liver disease; NASH: Non-alcoholic steatohepatitis.